AQR Capital Management LLC Raises Stock Holdings in Takeda Pharmaceutical Company Limited (NYSE:TAK)

AQR Capital Management LLC boosted its stake in Takeda Pharmaceutical Company Limited (NYSE:TAK) by 153.7% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 90,013 shares of the company’s stock after purchasing an additional 54,539 shares during the quarter. AQR Capital Management LLC’s holdings in Takeda Pharmaceutical were worth $1,165,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds have also bought and sold shares of the stock. Rise Advisors LLC purchased a new stake in shares of Takeda Pharmaceutical during the 1st quarter valued at $26,000. GAMMA Investing LLC raised its position in Takeda Pharmaceutical by 50.9% during the first quarter. GAMMA Investing LLC now owns 2,864 shares of the company’s stock valued at $40,000 after purchasing an additional 966 shares in the last quarter. EverSource Wealth Advisors LLC boosted its holdings in shares of Takeda Pharmaceutical by 38.6% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 3,082 shares of the company’s stock worth $43,000 after purchasing an additional 859 shares in the last quarter. Headlands Technologies LLC bought a new position in shares of Takeda Pharmaceutical during the 2nd quarter valued at about $59,000. Finally, Blue Trust Inc. raised its holdings in shares of Takeda Pharmaceutical by 74.0% during the 2nd quarter. Blue Trust Inc. now owns 5,480 shares of the company’s stock valued at $76,000 after buying an additional 2,330 shares in the last quarter. 9.17% of the stock is currently owned by institutional investors.

Takeda Pharmaceutical Stock Performance

NYSE:TAK opened at $14.30 on Friday. Takeda Pharmaceutical Company Limited has a 1-year low of $12.57 and a 1-year high of $15.39. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.26 and a quick ratio of 0.74. The business has a 50 day moving average of $14.56 and a 200 day moving average of $13.75. The company has a market capitalization of $45.48 billion, a price-to-earnings ratio of 26.97, a PEG ratio of 0.27 and a beta of 0.54.

Takeda Pharmaceutical (NYSE:TAK) last announced its quarterly earnings data on Wednesday, July 31st. The company reported $0.56 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.37 by $0.19. Takeda Pharmaceutical had a net margin of 6.02% and a return on equity of 10.11%. The company had revenue of $7.75 billion during the quarter. On average, sell-side analysts predict that Takeda Pharmaceutical Company Limited will post 1.58 earnings per share for the current fiscal year.

Takeda Pharmaceutical Profile

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.